Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Molecule mark for diffuse large b-cell lymphoma treating guide and prognosis judgment

A lymphoma, B cell technology, applied in the field of hematology oncology and medicine, can solve the problem of not providing DLBCL histological heterogeneity and prognostic molecular markers

Inactive Publication Date: 2009-07-01
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] However, the prior art does not provide molecular markers that can robustly reveal histological heterogeneity and prognosis in DLBCL

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecule mark for diffuse large b-cell lymphoma treating guide and prognosis judgment
  • Molecule mark for diffuse large b-cell lymphoma treating guide and prognosis judgment
  • Molecule mark for diffuse large b-cell lymphoma treating guide and prognosis judgment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Example 1. Specimen collection

[0086] The cases included in this study were 73 newly diagnosed DLBCL patients, including 42 males and 31 females, aged 22-80 years, with a median age of 53 years. The following clinical data of patients were collected: gender, age, behavioral status, Ann Arbor clinical stage, LDH level, number of extranodal lesions, and tumor size, and were scored according to the International Prognostic Index (IPI). The patients signed the informed consent according to the requirements of the institution. Patients received 6 courses of standard dose CHOP or R-CHOP regimen, with or without radiotherapy according to the condition.

[0087] The specific composition of the CHOP regimen is as follows: Cyclophosphamide 750mg / m 2 , static push, the first day; Adriamycin 50mg / m 2 , static push, the first day; vincristine 1.4mg / m 2 (maximum dose, 2.0 mg), intravenously, on day 1; and prednisone 60 mg, orally, on days 1-5.

[0088] The specific composition...

Embodiment 2

[0091] Example 2. Immunohistochemical detection and result judgment

[0092] 1. Tissue Sample Processing

[0093] The 73 DLBCL samples were all fixed in formaldehyde. After histological and immunohistochemical analysis, two senior pathologists determined the tissue type according to the 2001 WHO lymphoma classification criteria.

[0094] Cut 3 micron slices, conventional dewaxing, dehydration, microwave antigen retrieval and natural cooling for 30 minutes, 1.5% hydrogen peroxide to remove endogenous peroxidase, 1% bovine serum albumin (BSA) to block at room temperature for 20 minutes, add the following Primary antibody: anti-p-Akt (Cell Signaling Technology, Beverly, MA), anti-YB-1 (Cell Signaling Technology, Beverly, MA), incubated at 4°C overnight, Dako EnvisionHRP (Dako Cytomation) labeled secondary antibody, DAB color development, Gradient alcohol dehydration, xylene translucent, hematoxylin counterstained nuclei.

[0095] Select 10 representative fields of view under ...

Embodiment 3

[0099] Example 3. p-Akt, YB-1 detection results and curative effect analysis

[0100] 1. Immunohistochemical test results

[0101] The positive rates of p-Akt and YB-1 in DLBCL paraffin tissues were 54.8% (40 / 73) and 65.8% (48 / 73), respectively. Both p-Akt and YB-1 were positively localized in the cytoplasm, and stained in brownish-yellow uniform flakes. Strong YB-1 positive can be manifested as brown granular staining of cell membrane, perinucleus and nucleus. Such as Figure 1 ~ Figure 3 shown.

[0102] 2. The relationship between the expression of p-Akt and YB-1 and the prognosis under different treatment regimens

[0103] Among the 73 patients enrolled, the one-way X2 test showed that p-Akt - The overall effective rate of treatment for patients was 91.0%, p-Akt + The overall effective rate of the patients was 60.0%, and there was a statistical difference between the two (P=0.003). Similarly, those with positive expression of YB-1 had a low overall response rate ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a molecular mark (p-Akt and / or YB-1) for selecting treatment scheme and / or prognostic evaluation of diffuse large b-cell lymphomas and an application therefore, and relates to a method for selecting treatment scheme and / or prognostic evaluation of diffuse large b-cell lymphomas. The molecular mark p-Akt and / or YB-1 can simply and correctly judge the prognosis of diffuse large b-cell lymphomas, to select objective treatment scheme for patients, thereby improving the prognosis effect of treatment scheme and saving medical cost.

Description

technical field [0001] The present invention relates to the fields of hematology-oncology and medicine. More specifically, it relates to a molecular target for diffuse large B-cell lymphoma treatment plan selection and / or prognosis evaluation and a kit for detecting the target. Background technique [0002] Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting for about 30-40% of non-Hodgkin's lymphoma in adults. The current incidence of non-Hodgkin's lymphoma in my country is about 3-4 / 100,000, and it is increasing at a rate of 2-3% per year, among which diffuse large B-cell lymphoma (DLBCL) is the most common, accounting for about 50% of tumors, therefore, the annual national new cases are about 20,000-30,000. [0003] DLBCL has significant biological heterogeneity and can respond quite differently to treatment. The response of patients to treatment varies significantly. Conventional CHOP combined with chemotherapy (cyclophosphamide,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/53G01N33/68
Inventor 李军民张庆华徐子真赵维莅沈志祥
Owner RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com